Courtney Fitzhugh, M.D.

Lasker Clinical Research Scholar

Laboratory of Early Sickle Mortality Prevention


Building 10, Room 6N240A
10 Center Drive
Bethesda, MD 20814


Research Topics

Dr. Fitzhugh is exploring new avenues of hematopoietic stem cell (HSC) transplantation for sickle cell disease (SCD), while also studying the currently underexplored cardiovascular complications arising due to this genetic blood disorder.

Currently, HSC transplantation offers the only real cure for patients with SCD, though the transplantation procedure can only be applied to select people, and it carries its own set of health risks. One risk is that traditional stem cell transplants involve near total destruction of existing bone marrow, thus severely immunocompromising the transplant recipient. Dr. Fitzhugh and her team have been developing an alternative approach in which the donor and recipient stem cells coexist, potentially reducing the risk for serious infections or other immune complications. Dr. Fitzhugh has demonstrated the efficacy of this non-myeloablative procedure in both mice and human volunteers, and is currently participating in a long-term follow-up study in people to see if they remain free of SCD.

Dr. Fitzhugh is also conducting a half-matched protocol to increase the number of people eligible for HSC transplantation. The current procedure requires a fully HLA-matched sibling donor, and less than 20% of SCD patients would qualify. Through a half-matched protocol, any immediate genetic relative (parents, children, and siblings) would be able to donate stem cells, though the immune system barriers and potential complications are greater. Dr. Fitzhugh is currently examining the feasibility of this approach in a clinical pilot study and studying in the laboratory why half-matched transplant is successful in some patients and not others.

Dr. Fitzhugh is also interested in learning more about death due to this disease. Though HSC transplantations are still rare, hydroxyurea and other treatments have made SCD far more manageable, and the median age of death for people with SCD is in their 40s. As adults with SCD get older, heart disease becomes a common cause of death, in part related to arrhythmias such as ventricular tachycardia and also due to congestive heart failure. Dr. Fitzhugh is examining why SCD patients develop heart disease, and what can be done to prevent or possibly even reverse heart-related complications in this population. Through these joint avenues of research, Dr. Fitzhugh's group is finding new avenues to help people with SCD live longer and healthier lives.


Courtney Fitzhugh received her B.S. magna cum laude from the University of California, Los Angeles in 1996, and her M.D. from the University of California, San Francisco in 2001. During medical school, Dr. Fitzhugh participated in the NIH Clinical Research Training Program, where she studied with Dr. John Tisdale at the NHLBI. After receiving her M.D., Dr. Fitzhugh completed a joint residency in internal medicine and pediatrics at Duke University Medical Center, and in 2005 she did a combined adult hematology and pediatric hematology-oncology fellowship at the NIH and Johns Hopkins Hospital. Dr. Fitzhugh returned to the NHLBI in 2007 and was appointed as Assistant Clinical Investigator in 2012 and Clinical Tenure Track Investigator in 2016. She is a member of the American Society of Hematology.

Selected Publications

  1. Ghannam JY, Xu X, Maric I, Dillon L, Li Y, Hsieh MM, Hourigan CS, Fitzhugh CD. Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation. Blood. 2020;135(14):1185-1188.

  2. Sachdev V, Hsieh M, Jeffries N, Noreuil A, Li W, Sidenko S, Hannoush H, Limerick E, Wilson D, Tisdale J, Fitzhugh C. Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease. Blood Adv. 2019;3(19):2816-2824.

  3. Limerick E, Fitzhugh C. Choice of Donor Source and Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Sickle Cell Disease. J Clin Med. 2019;8(11).

  4. Fitzhugh CD, Hsieh MM, Taylor T, Coles W, Roskom K, Wilson D, Wright E, Jeffries N, Gamper CJ, Powell J, Luznik L, Tisdale JF. Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Adv. 2017;1(11):652-661.

  5. Fitzhugh CD, Cordes S, Taylor T, Coles W, Roskom K, Link M, Hsieh MM, Tisdale JF. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood. 2017;130(17):1946-1948.

This page was last updated on August 21st, 2020